Seer
Seer is a public proteomics company (NASDAQ: SEER) that sells the Proteograph Product Suite, an integrated nanoparticle-based platform combining assay kits, automation instruments, and cloud software for deep plasma proteome profiling. It serves academic translational researchers, biopharma development teams, and biomarker discovery programs through direct sales, STAC services, and a global CRO network.
- Company typePublic
- Founded2017
- HeadquartersRedwood City, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Seer does
Seer is a public proteomics company (NASDAQ: SEER) founded in 2017 and headquartered in Redwood City, California, that develops and commercializes the Proteograph Product Suite for deep, unbiased plasma proteome profiling. The platform is built around proprietary engineered magnetic-core nanoparticles with tuned surface chemistries that form reproducible protein coronas when introduced to biofluids, compressing the dynamic range of the plasma proteome. The integrated offering comprises consumable assay kits (Proteograph ONE, XT, DIRECT), the SP200 automation instrument capable of processing over 1,000 samples per week per instrument with under a five-hour runtime, and the cloud-based Proteograph Analysis Suite (PAS). Independent peer-reviewed benchmarks report up to 10x more protein groups than conventional direct-digest methods. Seer holds 23 validated patent claims on the core nanoparticle-enrichment technology, supported a Protein Discovery Catalog of 36,000+ identified proteins across 1,900+ biological pathways, and has accumulated 84 peer-reviewed publications including work in Nature Genetics and Nature.
Seer serves academic translational researchers, biopharmaceutical development teams, and biomarker discovery programs through three access pathways: direct instrument sales for high-volume in-house users, the Seer Technology Access Center (STAC) managed service for customers without mass spectrometry capabilities, and a global network of CRO service providers and Centers of Excellence. The revenue model combines capital equipment sales (SP100, SP200, SP200t instruments with 12-month warranties and optional service plans), recurring consumable revenue tied to the install base, bundled software licenses, and fee-for-service STAC projects priced on sample volume. Pricing is quote-based and not publicly disclosed. The instrument installed base reached 82 units by Q4 2025 (up 67% YoY), with consumable sample volumes up 69% YoY, though reported revenue declined 34% YoY in Q1 2026 amid academic funding pressure and NIH uncertainty.
The company went public in December 2020 and ended Q1 2026 with approximately $220 million in cash and investments against a market capitalization of approximately $101-111 million, meaning the equity trades below the cash position. Seer is currently navigating an activist proxy contest with the Radoff-JEC Group (7.7% owner), which has submitted three unsolicited acquisition proposals at $2.25-$2.40 per share, all rejected by the board. The board has separately filed an ITC complaint and federal lawsuit against Nanomics Biotechnology to defend its nanoparticle-enrichment patents, while continuing large operating losses near $70-100M annually.
Seer firmographics
Firmographics- Name
- Seer
- Legal name
- Seer, Inc.
- Website
- https://seer.bio
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Seer is a public proteomics company (NASDAQ: SEER) that sells the Proteograph Product Suite, an integrated nanoparticle-based platform combining assay kits, automation instruments, and cloud software for deep plasma proteome profiling. It serves academic translational researchers, biopharma development teams, and biomarker discovery programs through direct sales, STAC services, and a global CRO network.
- Ownership category
- akta.pro rank
Seer industry classification
Industry- Product category
- Proteomics Instrumentation and Consumables
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)
- akta.pro secondary industries
- Proteomics & Mass Spectrometry Services (HLAGANAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)
Keywords
Where Seer is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Seer business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Instruments (SP100, SP200, SP200t): Capital equipment sales of automation instruments for proteomics sample preparation, sold with 12-month warranties and optional extended service plans. Title passes to customer upon shipment.
- Consumables (Assay Kits): Recurring revenue from single-use assay kits including Proteograph ONE, XT, and DIRECT assays, consisting of nanoparticles and reagents. Consumables must be purchased alongside instruments and are single-use only.
- Software Licenses (ICS, PAS): Software licenses for instrument control (ICS) and data analysis (PAS) provided in object code, bundled with instrument purchase and maintained during warranty period.
- STAC Services: Fee-for-service proteomics analysis through Seer Technology Access Center, providing end-to-end sample processing, mass spectrometry, and bioinformatics for customers without in-house capabilities.
- Service Provider Network: CRO partners provide proteomics services using Seer technology, creating distributed service revenue ecosystem across global regions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Instrument Purchase - SP100, SP200, SP200t Automation Instruments |
| Unit Pricing | Pay-as-you-go | Consumables - Proteograph Assay Kits (ONE, XT, DIRECT) |
| Unit Pricing | Pay-as-you-go | STAC Standard Service Projects (21-500 samples) |
| Usage-based | Pay-as-you-go | STAC Proteograph Mass Spec Services (1000s of samples) |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels7 records
Seer product offering
Product offeringCore offering
Seer provides the Proteograph Product Suite, an integrated proteomics platform that uses proprietary engineered magnetic-core nanoparticles to form reproducible protein coronas from biofluids (primarily plasma), compressing dynamic range to enable deep, unbiased proteome coverage by mass spectrometry. The suite comprises consumable assay kits (Proteograph ONE, XT, DIRECT), the SP200 automation instrument, and the cloud-based Proteograph Analysis Suite (PAS) software. Customers can access the technology via in-house instrument purchase, the Seer Technology Access Center (STAC) fee-for-service, or through a global network of CRO service providers and Centers of Excellence.
Product overview
Seer offers the Proteograph Product Suite as an integrated proteomics platform. The core offering consists of engineered nanoparticle-based assay kits (Proteograph ONE Assay, Proteograph DIRECT Assay), the SP200 Automation Instrument for automated sample preparation, and the Proteograph Analysis Suite (PAS) cloud software for data analysis. Customers can access the technology through instrument purchase (in-house), the Seer Technology Access Center (STAC) managed service, or through certified service providers/CROs. The platform enables deep plasma proteome coverage, identifying up to 10x more proteins than traditional workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Proteograph Product Suite: Complete proteomics workflow including Proteograph ONE Assay, SP200 Automation Instrument, and Proteograph Analysis Suite for deep, unbiased plasma proteome analysis
- STAC (Seer Technology Access Center)
- Proteograph Analysis Suite (PAS)
- Seer Insights Program
Products and services
- Proteograph Product Suite Integrated proteomics workflow combining engineered nanoparticle assay kits, the SP200 automation instrument, and cloud-based analysis software for deep, unbiased, large-scale plasma proteome profiling for academic, biotech, pharma, and government researchers.
- Proteograph ONE Assay Single-use high-throughput assay kit for deep, reproducible, unbiased proteomic analysis that processes up to 80 samples at a time with one MS injection per sample, for population-scale proteomics studies.
- Proteograph DIRECT Assay
Quantifiable outcome
- Identifies up to 10x more protein groups than direct digest (neat) plasma methods
- +5 more outcomes
Companies that use Seer
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles3 records
Seer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature9 records
Seer partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, minor, strategic and regional.
- Korea UniversitycoreCollaboration to advance AI-driven plasma proteomics for multi-cancer screening. Preliminary data presented at ASMS 2026 analyzing 5,500+ plasma samples across ten cancer types. Ongoing collaboration expected to analyze more than 20,000 clinical plasma samples total.
- Brigham and Women's HospitalcoreCo-complainant with Seer in ITC complaint against Nanomics Biotechnology. Licensor of nanoparticle protein enrichment patent. Long-standing research collaborator with CEO Omid Farokhzad having served as Professor at Harvard Medical School directing the Center for Nanomedicine at Brigham and Women's Hospital.
- Nanomics Biotechnology Co., Ltd.minorRespondent in patent infringement complaint filed at ITC and federal district court. Seer seeking exclusion order to bar Nanomics' Proteonano kits and workstations from US market for alleged infringement of five U.S. patents.
- Precision Health Research, Singapore (PRECISE)coreCollaboration to provide proteomics analysis on 10,000 samples for landmark population-scale study. Integration with PRECISE-SG100K biobank initiative advancing population-scale proteomics research.
- RetinalGenix TechnologiesstrategicCollaboration to develop early detection biomarkers for neurodegenerative, systemic, and retinal diseases by combining retinal imaging with proteomic profiling. Partnership aims to identify molecular biomarkers before clinical symptoms appear.
- Thermo Fisher ScientificcoreSTAC service center uses Thermo Scientific Orbitrap Astral and Orbitrap Exploris 480 mass spectrometers, Vanquish Neo and Ultimate 3000 LC systems, and Pharmafluidics µPAC columns for proteomics analysis services.
- BrukercoreSTAC service center uses Bruker timsTOF HT and timsTOF SCP mass spectrometers with nanoElute and Ultimate 3000 LC systems. Note: Bruker subsidiaries (PreOmics, Biognosys) are also pursuing patent challenges against Seer.
- SciexcoreSTAC service center uses Sciex ZenoTOF 7600 mass spectrometer for proteomics analysis services.
- EvoteccoreEuropean CRO partner operating high-throughput multi-omics platform EVOpanOmics with >100,000 samples/year capacity using Seer Proteograph technology. Partner since 2022, expanding use beyond serum/plasma to CSF, urine, secretome and other biofluids.
- Soulbrain HoldingsregionalAsia Pacific channel partner (Korea) with domestic Proteograph platform business. Secured partnership in Q1 2022 and launched premier services in Korea for broad-scale proteomic profiling.
- Panome BioregionalNorth American CRO service provider and Center of Excellence offering next-generation proteomics using Seer technology. Featured collaborator in Seer webinar programming.
- Discovery Life SciencesregionalGlobal biospecimen and specialty lab services provider offering proteomics using Seer technology for biomarker discovery and clinical trials.
- Cedars-Sinai Precision Biomarker LaboratoriesregionalCommercial CRO wholly owned by Cedars-Sinai Medical Center offering comprehensive proteomics services using Seer technology for precision medicine research.
- Sanford Burnham PrebysregionalAcademic proteomics core facility and Center of Excellence using Seer Proteograph Product Suite with three mass spectrometry platforms and automated sample preparation.
- AllumiqsregionalNorth American CRO partner dedicated to multiomics-driven solutions for biotech and biopharma researchers using Seer sample preparation tools and mass spectrometry services.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Seer competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Seer social profiles
Digital presenceSeer compliance and trust
Trust signalCompliance2 records
Seer financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seer leadership team
Management profileNumber of profiles
Profiles8 records
Seer funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seer M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seer
What does Seer do?
Seer provides the Proteograph Product Suite, an integrated proteomics platform that uses proprietary engineered magnetic-core nanoparticles to form reproducible protein coronas from biofluids (primarily plasma), compressing dynamic range to enable deep, unbiased proteome coverage by mass spectrometry. The suite comprises consumable assay kits (Proteograph ONE, XT, DIRECT), the SP200 automation instrument, and the cloud-based Proteograph Analysis Suite (PAS) software. Customers can access the technology via in-house instrument purchase, the Seer Technology Access Center (STAC) fee-for-service, or through a global network of CRO service providers and Centers of Excellence.
Is Seer a public or private company?
Seer is a public company. It is classified as public and is currently operating.
When was Seer founded?
Seer was founded in 2017. It employs 101 to 250 people.
Where is Seer based?
Seer is headquartered in Redwood City, United States, in the North America region.
How does Seer make money?
Five revenue lines are on record. Instruments (SP100, SP200, SP200t) is the primary driver. The others are consumables (Assay Kits), software Licenses (ICS, PAS), STAC Services and service Provider Network.
Does Seer have an API?
No public API is recorded for Seer.
What industry is Seer in?
Seer's product category is Proteomics Instrumentation and Consumables. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 334516 and its SIC code is 3826.